Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology
Portfolio Pulse from
Inventiva published results from a clinical trial showing that lanifibranor significantly improves insulin resistance in patients with T2D and MASLD. The study was published in the Journal of Hepatology.
January 29, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inventiva's clinical trial results for lanifibranor show significant improvement in insulin resistance for T2D and MASLD patients, potentially boosting investor confidence.
The publication of positive clinical trial results in a peer-reviewed journal is likely to enhance the credibility of Inventiva's product, lanifibranor, and may lead to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90